5 minute read
Jan. 28, 2023

Emraclidine: A Pioneering M4 Positive Allosteric Modulator

emraclidine

M4 positive allosteric modulator Ph. II for schizophrenia discovery not disclosed Lancet, December 17, 2022 Cerevel Therapeutics, Cambridge, MA

drughunter.com
Drug Hunter Team

Emraclidine (CVL-231) is a selective positive allosteric modulator (PAM) of the cholinergic M4 muscarinic receptor (GCPR) and is the only selective M4 PAM in clinical development . The molecule was highlighted by Cerevel at JPM ‘23 as it has shown promising early results in schizophrenia with several Ph. II trials enrolling ( [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in